198 related articles for article (PubMed ID: 23085694)
21. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
22. Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.
Dos Santos LC; Ribeiro JC; Silva NP; Cerutti J; da Silva MR; Chauffaille Mde L
Rev Bras Hematol Hemoter; 2011; 33(6):417-24. PubMed ID: 23049357
[TBL] [Abstract][Full Text] [Related]
23. Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders.
Pastore C; Nomdedeu J; Volpe G; Guerrasio A; Cambrin GR; Parvis G; Pautasso M; Daglio C; Mazza U; Saglio G
Genes Chromosomes Cancer; 1995 Oct; 14(2):106-11. PubMed ID: 8527391
[TBL] [Abstract][Full Text] [Related]
24. Transformation of polycythemia vera to chronic myelogenous leukemia.
Mirza I; Frantz C; Clarke G; Voth AJ; Turner R
Arch Pathol Lab Med; 2007 Nov; 131(11):1719-24. PubMed ID: 17979493
[TBL] [Abstract][Full Text] [Related]
25. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML.
Honda H; Ushijima T; Wakazono K; Oda H; Tanaka Y; Aizawa Si; Ishikawa T; Yazaki Y; Hirai H
Blood; 2000 Feb; 95(4):1144-50. PubMed ID: 10666183
[TBL] [Abstract][Full Text] [Related]
26. Differences between blastic chronic myeloid leukemia and Ph-positive acute leukemia.
Berger R
Leuk Lymphoma; 1993; 11 Suppl 1():235-7. PubMed ID: 8251902
[TBL] [Abstract][Full Text] [Related]
27. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
28. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
[TBL] [Abstract][Full Text] [Related]
29. Phenotype of blasts in chronic myeloid leukemia in blastic phase-Analysis of bone marrow trephine biopsies and correlation with cytogenetics.
Reid AG; De Melo VA; Elderfield K; Clark I; Marin D; Apperley J; Naresh KN
Leuk Res; 2009 Mar; 33(3):418-25. PubMed ID: 18760473
[TBL] [Abstract][Full Text] [Related]
30. [Research progress on gene mutation of jak2].
Liu L; Li W; Liu N; Pang L; Feng SX; Zhao LL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1629-32. PubMed ID: 20030962
[TBL] [Abstract][Full Text] [Related]
31. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
32. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
[TBL] [Abstract][Full Text] [Related]
33. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
34. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
35. Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.
Martinelli G; Zaccaria A; Farabegoli P; Buzzi M; Testoni N; Bragliani M; Panzica G; Tura S
Leuk Lymphoma; 1993; 11 Suppl 1():51-6. PubMed ID: 8251917
[TBL] [Abstract][Full Text] [Related]
36. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
37. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
38. CEBPA mutation in a case of chronic myeloid leukemia presenting in myeloid blast crisis.
Yin Y; Li J; Yan W; Cheng Z; Sun N; Zhang G
Leuk Lymphoma; 2017 Mar; 58(3):708-710. PubMed ID: 27379703
[No Abstract] [Full Text] [Related]
39. Karyotypic changes during the course of blastic crisis of chronic myelogenous leukemia.
Mitani K; Miyazono K; Urabe A; Takaku F
Cancer Genet Cytogenet; 1989 Jun; 39(2):299-300. PubMed ID: 2752380
[No Abstract] [Full Text] [Related]
40. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
